Patient and disease characteristics at transplantation
. | Sibling . | VUD . | All . |
|---|---|---|---|
| Patients | 24 | 38 | 62 |
| Median age, y (range) | 56 (41-70) | 52 (22-65) | 53 (22-70) |
| Median time from diagnosis, mo (range) | 12 (5-60) | 16 (6-48) | 15 (5-60) |
| Median donor age, y (range) | 56 (40-68) | 36 (22-47) | 42 (22-68) |
| Disease status at transplantation | |||
| CKR, no. in remission/no. with cytogenetic abnormality at diagnosis | 8/11 | 6/22 | 14/33 |
| CMpR | 14 | 21 | 35 |
| PR | 3 | 2 | 5 |
| PD/relapse | 2 | 2 | 4 |
| Stable | 5 | 13 | 18 |
| CMV status, recipient/donor | |||
| Positive/positive | 14 | 4 | 18 |
| Positive/negative | 3 | 15 | 18 |
| Negative/positive | 1 | 2 | 3 |
| Negative/negative | 6 | 17 | 23 |
| Stem cell source, PBSC/BM | 22/2 | 19/19 | 41/21 |
| HLA disparity | 0 | 13 | 13 |
| Class I major, 1 Ag | 7 | 7 | |
| Class I minor, 1 Ag | 4 | 4 | |
| Class I major and minor, 2 Ag | 1 | 1 | |
| Class II minor, 1 Ag | 2 | 2 | |
| CD34 dose, × 106/kg (range) | 4.6 (1.9-17.5) | 4.2 (0.4-17.3) | 4.4 (0.44-17.5) |
| Days until neutrophil engraftment greater than 0.5 × 109/L (range) | 14 (9-57) | 15 (11-27) | 14 (9-57) |
| Days until platelet engraftment greater than 20 × 109/L (range) | 15 (7-105) | 17 (9-42) | 16 (7-105) |
. | Sibling . | VUD . | All . |
|---|---|---|---|
| Patients | 24 | 38 | 62 |
| Median age, y (range) | 56 (41-70) | 52 (22-65) | 53 (22-70) |
| Median time from diagnosis, mo (range) | 12 (5-60) | 16 (6-48) | 15 (5-60) |
| Median donor age, y (range) | 56 (40-68) | 36 (22-47) | 42 (22-68) |
| Disease status at transplantation | |||
| CKR, no. in remission/no. with cytogenetic abnormality at diagnosis | 8/11 | 6/22 | 14/33 |
| CMpR | 14 | 21 | 35 |
| PR | 3 | 2 | 5 |
| PD/relapse | 2 | 2 | 4 |
| Stable | 5 | 13 | 18 |
| CMV status, recipient/donor | |||
| Positive/positive | 14 | 4 | 18 |
| Positive/negative | 3 | 15 | 18 |
| Negative/positive | 1 | 2 | 3 |
| Negative/negative | 6 | 17 | 23 |
| Stem cell source, PBSC/BM | 22/2 | 19/19 | 41/21 |
| HLA disparity | 0 | 13 | 13 |
| Class I major, 1 Ag | 7 | 7 | |
| Class I minor, 1 Ag | 4 | 4 | |
| Class I major and minor, 2 Ag | 1 | 1 | |
| Class II minor, 1 Ag | 2 | 2 | |
| CD34 dose, × 106/kg (range) | 4.6 (1.9-17.5) | 4.2 (0.4-17.3) | 4.4 (0.44-17.5) |
| Days until neutrophil engraftment greater than 0.5 × 109/L (range) | 14 (9-57) | 15 (11-27) | 14 (9-57) |
| Days until platelet engraftment greater than 20 × 109/L (range) | 15 (7-105) | 17 (9-42) | 16 (7-105) |
CKR indicates complete karyotypic remission, cytogenetic abnormality present at diagnosis no longer detectable and marrow blasts less than 5%; CMpR, complete morphologic remission, less than 5% bone marrow blasts irregardless of karyotype; PR, partial response, greater than 50% decrease in bone marrow blasts; PD, progressive disease, greater than 50% increase in bone marrow blasts; and Ag, antigen.